Illumina Inc(ILMN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 37.51 | EPS (ttm) | 5.37 | Insider Own | 0.27% | Shs Outstand | 151.0M | Perf Week | -5.62% |
| Market Cap | 30.39B | Forward P/E | 33.09 | EPS next Y | 13.62% | Insider Trans | -88.26% | Shs Float | 150.6M | Perf Month | 4.37% |
| Enterprise Value | 31.75B | PEG | 2.51 | EPS next Q | 1.36 | Inst Own | 103.73% | Short Float | 6.29% | Perf Quarter | 23.88% |
| Income | 0.82B | P/S | 6.76 | EPS this Y | 10.6% | Inst Trans | -0.42% | Short Ratio | 4.89 | Perf Half Y | 65.65% |
| Sales | 4.50B | P/B | 10.71 | EPS next 5Y | 13.19% | ROA | 12.95% | Short Interest | 9.46M | Perf YTD | 53.45% |
| Book/sh | 18.79 | P/C | 26.02 | EPS past 3/5Y | - 4.22% | ROE | 32.38% | 52W High | -13.17% ($231.81) | Perf Year | 110.78% |
| Cash/sh | 7.74 | P/FCF | 32.64 | Sales past 3/5Y | -1.82% 6.02% | ROIC | 17.25% | 52W Low | 128.72% ($88.00) | Perf 3Y | 30.78% |
| Dividend Est. | - | EV/EBITDA | 27.23 | EPS Y/Y TTM | -31.78% | Gross Margin | 66.81% | Volatility(W/M) | 4.04% 4.14% | Perf 5Y | -54.8% |
| Dividend TTM | - | EV/Sales | 7.06 | Sales Y/Y TTM | 4.97% | Oper. Margin | 19.87% | ATR (14) | 8.63 | Perf 10Y | 25.63% |
| Dividend Ex-Date | - | Quick Ratio | 1.4 | EPS Q/Q | -9.61% | Profit Margin | 18.35% | RSI (14) | 45.62 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.8 | Sales Q/Q | 9.84% | SMA20 | -4.39% ($210.51) | Beta | 1.46 | Target Price | $204.63 |
| Payout | - | Debt/Eq | 0.89 | Earnings | 2026/7/30 | SMA50 | 0.71% ($199.85) | Rel Volume | 0.67 | Prev Close | $205 |
| Employees | 8600 | LT Debt/Eq | 0.69 | EPS/Sales Surpr. | 6.83% 2.51% | SMA200 | 31.42% ($153.15) | Avg Volume(3M) | 1.94M | Price | $201.27 |
| IPO | 2000/7/28 | Option/Short | Yes/Yes | Trades | 24118 | Volume | 1,289,702 | Change | -1.82% |
Company
ILMN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Illumina Inc is a leading global company in the next-generation sequencing (NGS) field. It supplies high-throughput sequencing instruments and dedicated reagents for genetic analysis, driving growth in the biotechnology research and diagnostics markets. With a large installed base at research institutes and medical institutions worldwide, the company has built a stable consumables revenue structure.
Over the past 1 year, on the higher side
13% below its 1-year high.
ILMN makes money exceptionally well
Strong earnings and excellent financial health
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +10.6% this year.
Tap to view numbers
The price looks about right
Trading at 37.5 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +30.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 103.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.05%
EKG 0.05%
GNOM 0.05%
ARKG 0.04%
FBT 0.04%It ranks #4 in the industry
Based on market cap of $30B.
ILMN $30B PER 37.5
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is ILMN?
ILMN belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ILMN?
The market cap of ILMN is approximately $30.4B, ranking 458 within its sector.
What is the P/E ratio of ILMN?
ILMN has a P/E ratio of approximately 37.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ILMN?
ILMN has recorded a 52-week high of $231.81 and a low of $88.00.
